VolumeVol. 60 • Number No. 2 • April - June 2022 Back
A Population-based Cross-sectional Study of the Status of Diabetes Care in the Philippines (PhilDiabCare 2020)
Authors: Ernesto L. Ang, Araceli A. Panelo, Leorino M. Sobrepeña, Rima T. Tan, Richard Elwyn Fernando, Marcelo A. Lim, Jose Ronilo G. Juangco
DOI: 10.65564/pjim.a0887625f1
Date of Publication: June 2022
Abstract
Background. Worldwide, diabetes mellitus (DM) is a serious health issue with a global prevalence of 9.8% in 2021. According to the latest 2018 Expanded National Health and Nutrition survey done by the DOST-FNRI, the prevalence of diabetes in the Philippines have more than doubled from 3.4% in 2003 to 7.9% in 2018. The latest research conducted regarding diabetes care in the Philippines was in 2008 which showed that 85% of patients with diabetes failed to achieve the HbA1c general target of <7%.
Objectives. A population-based cross-sectional study to update the current status of diabetes care in the Philippines, specifically to determine glycemic control, trends in DM management, prevalence of complications and lastly their clinico-socio demographic profile.
Methods. 340 patients with diabetes were included from the clinics of the Institute for Studies on Diabetes Foundation, Inc. physicians. The following data were collected: clinico-socio demographic profile, HbA1C-based glycemic control, trend in the use of glucose lowering agents, and prevalence of diabetes complications.
Results. The mean age of the 340 patients with diabetes in this study was 62 years old. Almost sixty-seven percent (66.8%) were females. The mean body mass index was 26 kg/m2. The mean duration of diabetes was 12.63 years. Close to sixty-eight percent (67.6%) had tertiary education, 58.8% were unemployed and 65% had above minimum income.
The most commonly used single oral agent was biguanide (72.9%), followed by dipeptidyl peptidase-4 inhibitors (64.3%). The most common dual therapy combinations were biguanide plus dipeptidyl peptidase-4 inhibitors (43.2%), biguanide plus sulfonylureas (27.2%), and biguanide plus sodium-glucose co-transporter-2 inhibitors (11.1%). Basal insulin was the most commonly used injectable agent.
The present study showed that 47.4% of patients achieved an HbA1c of <7%. For the microvascular complication group alone, most had neuropathy (30.4%) followed by nephropathy (17.3%) and by retinopathy (5.4%). For the macrovascular complication group, the most common was coronary artery disease (82%) followed by peripheral artery disease and DM foot (27%). Overall, the most frequent DM complication identified was neuropathy (30.4%) , nephropathy (17.3%) and coronary heart disease (16.1%).
Discussion. Compared to the 2008 study, oral glucose lowering agents’ usage shifted from sulfonylureas to more use of dipeptidyl peptidase-4 inhibitors. There was a decline in the use of thiazolidinediones, α-glucosidase inhibitors and non-use of meglitinides. For insulin use, there was a shift from the use of premixed insulin to more basal insulin usage.
There was marked improvement in the diabetes care situation in the Philippines from the 2008 study to the 2020 study. Glycemic control defined as HbA1c level of <7.0 increased from 15% to 47.4%. Coronary artery disease was the most common macrovascular complication while neuropathy was the most common overall and microvascular complication.
Keywords: HbA1c, Diabetes Complications, PhilDiabCare, Glycemic Control, T2DM, Comorbidities, Management
References
- Magliano, D. J., et.al. (n.d.). IDF Diabetes Atlas 2021 10th edition. IDF Diabetes Atlas. Retrieved December 2021, from https://diabetesatlas.org/atlas/tenth-edition/
- Causes of Deaths in the Philippines (Preliminary): January to December 2020. Philippine Statistics Authority. (2022, January 31) from https://psa.gov.ph/content/registered-deaths-philippines-2020
- IDF BRIDGES. International Diabetes Federation - Home. (n.d.). from https://www.idf.org/our-activities/epidemiology-research/bridges?language=ar Accessed 08-29,2016
- 2018 Expanded National Nutrition Survey. (ENNS) DOST-FNRI. (2018). Retrieved January 2022, from http://enutrition.fnri.dost.gov.ph/site/uploads/2018 _ENNS_Facts_and_Figures.pdf: 144-146
- Jimeno, Cecilia A., Leorino M. Sobrepena, and Roberto C. Mirasol. "DiabCare 2008: Survey on glycaemic control and the status of diabetes care and complications among patients with type 2 diabetes mellitus in the Philippines." Philippine Journal of Internal Medicine 50.1 (2012): 15-22.
- Cholil AR, Lindarto D, Pemayun TGD, Wisnu W, Kumala P, Puteri HHS. DiabCare Asia 2012: diabetes management, control, and complications in patients with type 2 diabetes in Indonesia. Med J Indones [Internet]. 2019May8 [cited 2021Feb.20];28(1):47-6. Available from:https://mji.ui.ac.id/journal/index.php /mji/ article/view/2931
- Centers for Disease Control and Prevention. National Diabetes Statistics Report, 2020. Atlanta, GA: Centers for Disease Control and Prevention, U.S. Dept of Health and Human Services; 2020.
- Chan J, So W, Ko G, Tong P, Yang X, Ma R, Kong A, Wong R, Le Coguiec F, Tamesis B, Wolthers T, Lyubomirsky G, Chow P. The Joint Asia Diabetes Evaluation (JADE) Program: a web-based program to translate evidence to clinical practice in Type 2 diabetes. Diabet Med. 2009 Jul;26(7):693-9. doi: 10.1111/j.1464-5491.2009.02751. x. PMID: 19573118.
- Nguyen, K.T., Diep, B.T.T., Nguyen, V.D.K. et al. A cross-sectional study to evaluate diabetes management, control and complications in 1631 patients with type 2 diabetes mellitus in Vietnam (DiabCare Asia). Int J Diabetes Dev Ctries 40, 70–79 (2020). https://doi.org/10.1007/s13410-019-00755-w
- Brath, H., Paldánius, P., Bader, G. et al. Differences in glycemic control across world regions: a post-hoc analysis in patients with type 2 diabetes mellitus on dual antidiabetes drug therapy. Nutr & Diabetes 6, e217 (2016). https://doi.org/10.1038/nutd.2016.25
- Borgharkar SS, Das SS. Real-world evidence of glycemic control among patients with type 2 diabetes mellitus in India: the TIGHT study. BMJ Open Diabetes Res Care. 2019 Jul 14;7(1): e000654. doi: 10.1136/bmjdrc-2019-000654. PMID: 31413840; PMCID: PMC6673766.
- Ngarmukos C, Bunnag P, Kosachunhanun N, Krittiyawong S, Leelawatana R, Prathipanawatr T, Plengvidhya N, Benjasuratwong Y, Suwanwalaikorn S, Deerochanawong C, Chetthakul T, Mongkolsomlit S, Rawdaree P. Thailand diabetes registry project: prevalence, characteristics and treatment of patients with diabetic nephropathy. J Med Assoc Thai. 2006 Aug;89 Suppl 1:S37-42. PMID: 17715832.
- Lee WR, Lim HS, Thai AC, Chew WL, Emmanuel S, Goh LG, Lau HC, Lee CH, Soon PC, Tambyah JA, Tan YT, Jorgensen LN, Chua A, Yeo JP; Diabcare Singapore Local Working Group & Diabetic Society of Singapore. A window on the current status of diabetes mellitus in Singapore--the Diabcare-Singapore 1998 study. Singapore Med J. 2001 Nov;42(11):501-7. PMID: 11876374.
- Tong PC, Ko GT, So WY, Chiang SC, Yang X, Kong AP, Ozaki R, Ma RC, Cockram CS, Chow CC, Chan JC. Use of anti-diabetic drugs and glycaemic control in type 2 diabetes-tThe Hong Kong Diabetes Registry. Diabetes Res Clin Pract. 2008 Dec;82(3):346-52. doi: 10.1016/j.diabres.2008.09.006. Epub 2008 Oct 15. PMID: 18926583.
- Choi YJ, Kim HC, Kim HM, Park SW, Kim J, Kim DJ. Prevalence and management of diabetes in Korean adults: Korea National Health and Nutrition Examination Surveys 1998-2005. Diabetes Care. 2009 Nov;32(11):2016-20. doi: 10.2337/dc08-2228. Epub 2009 Aug 12. PMID: 19675201; PMCID: PMC2768204.
- Gerry H. Tan, Diabetes Care in the Philippines Annals of Global Health, Volume 81, Issue 6, 2015, Pages 863-869, ISSN 2214-9996, https://doi.org/10.1016/j.aogh.2015.10.004from:https://www.sciencedirect.com/science/article/pii/S2214999615012643
- Fojas MC, Lantion-Ang FL, Jimeno CA, et al. Complications and cardiovascular risk factors among newly-diagnosed type 2 diabetics in Manila. Phil J Int Med 2009;47: 99e105. 32. Department of Medicine
- Pan C, Yang W, Jia W, Weng J, Tian H. Management of Chinese patients with type 2 diabetes, 1998-2006: the Diabcare-China surveys. Curr Med Res Opin. 2009 Jan;25(1):39-45. doi: 10.1185/03007990802586079. PMID: 1921013